XML 34 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences Corporation Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2020     636.4          
Beginning balance at Dec. 31, 2020 $ 4,574.3 $ 4,574.3 $ 636.4 $ (1,904.1) $ 1,438.1 $ 4,565.0 $ (161.1) $ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2020       12.1        
Increase (Decrease) in Stockholders' Equity                
Net income (loss) 1,503.1 1,503.1       1,503.1    
Other comprehensive income (loss), net of tax 3.4 3.4         3.4  
Common stock issued under equity plans (in shares)     5.6          
Common stock issued under equity plans 158.6 158.6 $ 5.6   153.0      
Stock-based compensation expense 109.3 109.3     109.3      
Purchases of treasury stock (in shares)       5.8        
Purchases of treasury stock (512.8) (512.8)   $ (512.8)        
Common stock, ending balance (in shares) at Dec. 31, 2021     642.0          
Ending balance at Dec. 31, 2021 5,835.9 5,835.9 $ 642.0 $ (2,416.9) 1,700.4 6,068.1 (157.7) 0.0
Treasury stock, ending balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity                
Net income (loss) 1,521.9 1,521.9       1,521.9    
Other comprehensive income (loss), net of tax (97.2) (97.2)         (97.2)  
Common stock issued under equity plans (in shares)     4.3          
Common stock issued under equity plans 146.4 146.4 $ 4.3   142.1      
Stock-based compensation expense 126.8 126.8     126.8      
Purchases of treasury stock (in shares)       20.1        
Purchases of treasury stock $ (1,727.1) (1,727.1)   $ (1,727.1)        
Common stock, ending balance (in shares) at Dec. 31, 2022 608.3   646.3          
Ending balance at Dec. 31, 2022 $ 5,806.7 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) 0.0
Treasury stock, ending balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity                
Net income (loss) $ 1,399.4 1,402.4       1,402.4   (3.0)
Other comprehensive income (loss), net of tax 12.1 12.1         12.1  
Common stock issued under equity plans (in shares)     4.2          
Common stock issued under equity plans 169.9 169.9 $ 4.2   165.7      
Stock-based compensation expense 139.4 139.4     139.4      
Purchases of treasury stock (in shares)       11.4        
Purchases of treasury stock (880.5) (880.5)   $ (880.5)        
Changes to noncontrolling interest (Note 9) $ 72.4             72.4
Common stock, ending balance (in shares) at Dec. 31, 2023 601.1   650.5          
Ending balance at Dec. 31, 2023 $ 6,719.4 $ 6,650.0 $ 650.5 $ (5,024.5) $ 2,274.4 $ 8,992.4 $ (242.8) $ 69.4
Treasury stock, ending balance (in shares) at Dec. 31, 2023 49.4     49.4